Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi-Aventis Merger Complete

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi-Aventis launches as the third largest pharmaceutical company in the world following completion of the Sanofi-Synthelabo/Aventis merger

You may also be interested in...



Sanofi-Aventis’ U.S. Headquarters

U.S. headquarters for Sanofi-Aventis will be located in Bridgewater, N.J., the firm announced Oct. 13.

Sanofi-Aventis’ U.S. Headquarters

U.S. headquarters for Sanofi-Aventis will be located in Bridgewater, N.J., the firm announced Oct. 13.

Sanofi, Bristol Discussing Changes To Avapro Agreement

Sanofi and Bristol-Myers Squibb are likely to make changes to the co-promotion for the antihypertensive Avapro, Sanofi said during an Aug. 31 analysts conference call

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060371

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel